BMS-554417

BMS-554417 is a novel, orally bioavailable small molecule inhibitor targeting both IGF-IR and insulin receptor kinase activity. It inhibits cell proliferation in vitro, induces cell cycle arrest or apoptosis, and demonstrates significant anti-tumor efficacy in xenograft models by blocking downstream PI3K/Akt and ERK signaling pathways. This makes it a valuable research tool for studying IGF/insulin signaling in oncology and metabolic disease research.